Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 30:3:16009.
doi: 10.1038/mto.2016.9. eCollection 2016.

High-content molecular profiling of T-cell therapy in oncology

Ruslan Novosiadly  1 , Michael Kalos  1
Affiliations
Review

High-content molecular profiling of T-cell therapy in oncology

Ruslan Novosiadly et al. Mol Ther Oncolytics. .

Abstract

Recent clinical data have revealed the remarkable potential for T-cell-modulating agents to induce potent and durable responses in a subset of cancer patients. In this review, we discuss molecular approaches, platforms, and strategies that enable a broader interrogation of the activity of agents that modulate the activity of tumor-specific T cells, to more comprehensively understand how and why the agents succeed and fail, as well as examples of data sets generated in clinical trials that have provided important insights into the biological activity of T-cell therapies and that support further rational development of this exciting treatment modality.

PubMed Disclaimer

Conflict of interest statement

R.N.—employee, with stock interests, Eli Lilly and Company. M.K.—employee, with stock interests, Eli Lilly and Company; named on issued patents related to CAR technology and licensed to Novartis Corporation; former member, science advisory board Adaptive Biotechnologies, stock option grant.

Figures

Figure 1
Figure 1
Scope and emerging platforms for translational research in immunooncology.
See this image and copyright information in PMC

References

    1. Rosenberg, SA and Restifo, NP (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348: 62–68. - PMC - PubMed
    1. Kalos, M and June, CH (2013). Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39: 49–60. - PMC - PubMed
    1. Huehls, AM, Coupet, TA and Sentman, CL (2015). Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 93: 290–296. - PMC - PubMed
    1. Oates, J, Hassan, NJ and Jakobsen, BK (2015). ImmTACs for targeted cancer therapy: Why, what, how, and which. Mol Immunol 67(2 Pt A): 67–74. - PubMed
    1. Topalian, SL, Drake, CG and Pardoll, DM (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27: 450–461. - PMC - PubMed